榮昌生物-B(09995.HK)擬收購醫藥研發設備用於研發活動
格隆匯5月3日丨榮昌生物-B(09995.HK)公佈,公司與煙台邁百瑞國際生物醫藥股份有限公司及其全資子公司邁百瑞生物醫藥(上海)有限公司於2021年5月3日分別簽署設備採購合同及採購合同。
根據設備採購合同,邁百瑞同意出售超濾系統、層析柱、蠕動泵等研發設備,代價為人民幣416.12萬元(含增值税人民幣47.87萬元),而根據採購合同,邁百瑞(上海)同意出售酶標儀、高效液相色譜儀、恆温培養搖牀等研發設備、週轉材料、原材料等,代價為人民幣1,247.26萬元。
邁百瑞及其附屬公司(包括邁百瑞(上海))是一家全球性的合同開發和製造機構,負責生物藥物的合同開發和製造,包括單克隆抗體,重組蛋白,抗體藥物結合物和雙特異性藥物。
公司表示,公司於2020年5月成立上海研發中心,為推進藥物研發急需採購相應設備及材料,因對外採購的週期較長,故公司向邁百瑞及邁百瑞(上海)收購相應存貨及資產用於公司的研發活動,前述交易有益於公司節約時間成本,提高研發效率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.